Targeting BCL-2 as a Therapeutic Strategy for Primary <i><sup>p210</sup>BCR-ABL1</i>-positive B-ALL Cells

Michele Massimino, Elena Tirrò, Stefania Stella, Maria Stella Pennisi, Silvia Rita Vitale, Adriana Puma, Chiara Romano, Sandra Di Gregorio, M. A. Romeo, Francesco Di Raimondo,

In Vivo · 2020 · 12 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

Background/Aim: Philadelphia-positive acute lymphoblastic leukemia (Ph + B-ALL) is caused by the malignant transformation of lymphoid cells induced by BCR-ABL1 constitutive catalytic activity. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML) cells, inducing durable hematological, cytogenetic and molecular responses. However, in Ph + B-ALL -as in CML progressing to blast crisis -TKIs fail to maintain disease remission. We, therefore, wanted to investigate if dual targeting of BCL-2 and BCR-ABL1 would be more effective in killing Ph + B-ALL cells. Materials and Methods: p210-B-ALL CD34-positive cells were used to evaluate the BCR-ABL expression and pharmacological targeting of BCL-2, by venetoclax, alone or in combination with BCR-ABL1 inhibition.

References

29